http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Absolute Named a Leader in the G2 Summer 2020 Grid Report for Endpoint Management
-
Abbott's FreeStyle® Libre 2 iCGM System Now Available to Medicare Beneficiaries
-
Abbott's (ABT) Fast, $5, 15-Minute, Easy-to-Use COVID-19 Antigen Test Receives FDA Emergency Use Authorization
-
Abbott's Fast, $5, 15-Minute, Easy-to-Use COVID-19 Antigen Test Receives FDA Emergency Use Authorization; Mobile App Displays Test Results to Help Our Return to Daily Life; Ramping Production to 50 Mi
-
Absolute Announces Filing of Shelf Prospectus
-
Absolute Reports Fiscal 2020 Fourth Quarter and Annual Financial Results
-
Abbott (ABT) Announces Start of Study to Evaluate New Device to Treat Recurrent Atrial Fibrillation
-
Abbott Announces Start of Study to Evaluate New Device to Treat Recurrent Atrial Fibrillation
-
Absolute Delivers New Platform Capabilities to Help Enterprises Meet Complex Compliance Requirements and Enable Autonomous, Self-Healing Endpoints
-
Absolute to Present at the Canaccord Genuity 40th Annual Growth Conference
-
Absolute to Host Conference Call for Fiscal 2020 Fourth Quarter and Annual Financial Results
-
Abbott (ABT) Receives FDA Approval for iOS-Compatible App Allowing People Living With Chronic Pain and Movement Disorders to Personalize Therapy Via Their Mobile Device
-
Abbott Receives FDA Approval for iOS-Compatible App Allowing People Living With Chronic Pain and Movement Disorders to Personalize Therapy Via Their Mobile Device
-
Absolute Declares Quarterly Dividend
-
Abbott Reports Second-Quarter 2020 Results, Exceeds Analysts' Expectations
-
Abbott (ABT) Agrees to Global Transcatheter Litigation Settlement with Edwards Lifesciences (EW)
-
Abbott Agrees to Global Transcatheter Litigation Settlement with Edwards Lifesciences
-
Abbott (ABT) Receives FDA Approval for New Heart Rhythm Devices Featuring Bluetooth Connectivity and Continuous Remote Monitoring
-
Abbott Receives FDA Approval for New Heart Rhythm Devices Featuring Bluetooth Connectivity and Continuous Remote Monitoring
-
K-12 Education Sector Turns to Absolute for Successful Distance Learning Programs Rooted in Endpoint Resilience
-
Abbott (ABT), Tandem Diabetes Care (TNDM) Advance Development of Integrated Technologies for Future Automated Insulin Delivery Systems
-
Abbott and Tandem Diabetes Care Advance Development of Integrated Technologies for Future Automated Insulin Delivery Systems
-
New Research Finds Abbott's Optical Coherence Tomography Imaging Changed Treatment Decisions in 88% of Artery Blockages
-
Abbott (ABT) Announces New Late-Breaking Data Highlight Impact of its Minimally Invasive Structural Heart Therapies
-
New Late-Breaking Data Highlight Impact of Abbott's Minimally Invasive Structural Heart Therapies
-
New Research from Absolute Underscores Vulnerability of Enterprise Devices and Critical Endpoint Controls, Reveals Opportunities to Optimize Security Investments
-
Abbott Hosts Conference Call for Second-Quarter Earnings
-
Absolute Expands Sensitive Data and Device Protections for Remote Endpoints with Enhancements to Undeletable Defense Platform
-
New Data Show Use of Abbott's FreeStyle® Libre System Reduces All-Cause, Diabetic Ketoacidosis-Related Hospitalization Rates and Acute Diabetes Events
-
Abbott (ABT) Reports FreeStyle Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes
-
Abbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards
-
New Late-Breaking Data Show Use of Abbott's FreeStyle® Libre System Significantly Reduces HbA1C Levels in People with Type 2 Diabetes Using Insulin or Not
-
Abbott Declares 386th Consecutive Quarterly Dividend
-
Anaheim Union High School District Protects Sizable Technology Investment with Absolute Endpoint Resilience
-
Pennsylvania Cyber Charter School Selects Absolute to Protect Mission-Critical Apps With Unbreakable Endpoint Resilience
-
Abbott (ABT) Releases Interim Clinical Study Data on ID NOW COVID-19 Rapid Test Showing Strong Agreement to Lab-Based Molecular PCR Tests
-
Abbott Releases Interim Clinical Study Data on ID NOW COVID-19 Rapid Test Showing Strong Agreement to Lab-Based Molecular PCR Tests
-
Absolute Honored as a Finalist in Two Categories for BC Tech Association’s 2020 Technology Impact Awards
-
Abbott (ABT) Announces Contract to Supply Millions of IgG Lab-Based Antibody Tests to the UK Government
-
Abbott Announces Contract to Supply Millions of IgG Lab-Based Antibody Tests to the UK Government
-
Duarte Unified School District Protects Students While Fostering Student Engagement With Absolute Web Usage
-
Absolute Powers K-12 Distance Learning Programs with the Launch of Web Usage
-
Abbott Provides Update on ID NOW™
-
Absolute to Present at 15th Annual Needham Virtual Technology & Media Conference
-
Abbott (ABT) Receives FDA Emergency Use Authorization for COVID-19 Molecular Test on New Alinity m System
-
Abbott Receives FDA Emergency Use Authorization for COVID-19 Molecular Test on New Alinity™ m System
-
Absolute Reports Fiscal 2020 Third Quarter Financial Results
-
Abbott (ABT) Receives FDA Emergency Use Authorization for COVID-19 Antibody Blood Test on Alinity i System
-
Abbott Receives FDA Emergency Use Authorization for COVID-19 Antibody Blood Test on Alinity™ i System
-
Abbott (ABT) Says Research from University of Washington Demonstrates High Performance of its SARS-CoV-2 Antibody Blood Test

